Mario arrived on life support — ultra-rapid WGS confirmed why he needed a heart transplant
We are heading up a newborn sequencing consortium that will revolutionize and shorten the diagnostic journey.
We’re setting a new standard of care for newborns and children with rare undiagnosed diseases.
Inozyme is seeking patients with disease-causing variants in the ENPP1 and/or ABCC6 genes for possible participation in a clinical trial.
Rady Childrens Institute for Genomic Medicine (RCIGM), a non-profit research institute enabling rapid diagnosis and targeted treatment of critically ill newborns and pediatric patients, is proud to announce that Aaron D. Besterman, MD, received a Young Investigator Grant from the Brain & Behavior Research Foundation.
PATIENT WORTHY: Catherine Nester spoke with Patient Worthy about the importance of newborn screening, the challenges of diagnostic delays, and how Inozyme is working to transform the treatment landscape for ENPP1 Deficiency and ABCC6 Deficiency, also known as Generalized Arterial Calcification of Infancy (GACI) types 1 and 2, respectively.
Thursday November 30, 2023 | 12pm ET
*Free Registration is required
Saturday November 18, 2023 | 10:45am
Rapid Precision Medicine™ is here now. We are setting the standard for pediatric critical care by breaking barriers to expand access to genomically-informed, personalized care nationwide. We offer many opportunities to collaborate with as we work to save and improve lives.
© 2023 Rady Children's Institute for Genomic Medicine.
